Primary antibody deficiency-associated arthritis shares features with spondyloarthritis and enteropathic arthritis

Abstract

Objective

The clinical spectrum of primary antibody deficiencies (PADs) and especially common variable immunodeficiency (CVID) includes various autoimmune disorders. We studied the prevalence and the features of articular rheumatic disease in a cohort of patient with PADs.

Methods

In this retrospective cohort study, complete clinical data of 268 patients with PADs, mainly consisting of patients with CVID, visiting the immunology outpatient clinic of a German tertiary hospital between 2018 and 2021 were collected. Those included case history, physical examination, laboratory as well as radiological findings.

Results

Inflammatory arthritis was diagnosed in 16.4% of studied patients and was significantly more common among patients with PAD-associated enteropathy (OR 13.39, p=0.0001), splenomegaly (OR 6.09, p=0.0001) or atopic diseases (OR 3.31, p=0.021). Given HLA-B27 status, the involvement of the axial skeleton and the presence of features, such as anterior uveitis, inflammatory bowel disease, psoriasis and/or dactylitis, 75% of studied patients fulfilled the Assessment of Spondyloarthritis International Society classification criteria.

Conclusion

PAD-associated arthritis frequently shares features with spondyloarthritis (SpA) and enteropathic arthritis. The latter may suggest the interconnected pathomechanisms of inflammatory arthritis in SpA and PADs.

Correspondence to Dr Georgios Sogkas; [email protected]

WHAT IS ALREADY KNOWN ON THIS TOPIC

• Primary antibody deficiencies (PADs), especially common variable immunodeficiency, are often associated with autoimmunity, including rheumatic disorders.

WHAT THIS STUDY ADDS

• This is the first study characterising the clinical spectrum of inflammatory arthritis in PADs.

• Arthritis in PADs is classified as a spondyloarthritis (SpA) or an enteropathic arthritis in 75% of studied patients.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

• Association of inflammatory arthritis in PADs with PAD-related enteropathies lends credence to the gut–joint axis hypothesis, proposed for the pathogenesis of SpA.

• The diagnosis of an underlying PAD may be considered in patients with an enteropathic arthritis.

Introduction

Primary antibody deficiencies (PADs) comprise a heterogeneous group of disorders characterised by ineffective humoral immunity.¹ Besides recurrent infections, especially due to encapsulated bacteria such as Streptococcus pneumoniae and Haemophilus influenzae, PADs manifest with variable immune dysregulation, including allergy, granulomatous disease, autoimmunity, autoinflammation and benign lymphoproliferation.² The common variable immunodeficiency (CVID) has an estimated prevalence of 1:10 000–1:100 000 and is considered the most prevalent symptomatic PAD disorder.³ Autoimmunity in CVID is heterogeneous and commonly manifests as an autoimmune cytopenia or an autoimmune endocrinopathy.^{3 4} Further, CVID is associated with rheumatic articular and connective tissue diseases.⁴ Rheumatic disorders and especially inflammatory arthritis have also been reported in X-linked agammaglobulinaemia (XLA) and isolated IgG subclass deficiency.^5–8

Previous studies have reported a varying prevalence of inflammatory arthritis in CVID, ranging from 1% to 11.5% in different patient cohorts.^9–12 Rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) have been commonly reported in CVID.^12–14 Polyarticular JIA and RA have been reported to represent relatively common autoimmune manifestations in XLA and isolated IgG subclass deficiency, respectively.^5–8 However, inflammatory arthritis remains a poorly characterised manifestation of PADs. In the present study, we aimed to establish the prevalence of inflammatory arthritis in a German cohort of patients with PADs and characterise its clinical, laboratory and radiological features.

Patients and methods

Study cohort

This single-centre retrospective study included a total of 268 patients with PAD visiting the immunology outpatient clinics of the department of rheumatology and immunology of the Hannover Medical School.

Data were collected from 2018 to 2021. Diagnosis of primary immunodeficiency was based on the current European Society for Immunodeficiencies diagnostic criteria (available at http://esid.org/Working-Parties/Registry/Diagnosis-criteria).¹⁵ Clinical data were obtained from patients’ medical files. PAD-associated phenotypes were documented as described previously.¹⁶ In particular, those included bronchiectasis (CT-confirmed), autoimmune cytopenias, such as autoimmune haemolytic anaemia (AIHA), idiopathic thrombocytopenic purpura (ITP), organ-specific autoimmunity (including vitiligo, psoriasis, insulin-dependent diabetes mellitus, thyroidopathies, atrophic gastritis and arthritis), granulomatous disease, enteropathy and malignancies. Interstitial lung disease (ILD) was diagnosed based on typical CT scan findings, in the absence of evidence for aninfectious or alternative cause. Splenomegaly was defined as spleen enlargement of ≥11 cm on palpation or ultrasound, including previous splenectomy of an enlarged spleen. Lymphadenopathy was detected on palpation, ultrasound, CT or magnetic resonance scan. Granulomatous disease was definedas at least one biopsy-proven unexplained granuloma, excluding Crohn’s disease-associated granulomas.Enteropathy included all cases of biopsy-proven non-infectious inflammatory bowel disease (IBD) (ulcerative colitis and Crohn's disease), coeliac disease, lymphocytic infiltration of the interepithelial mucous, the lamina propria and/or the submucosa, as well as patients with chronic idiopathic diarrhoea. Malignancies included haematological and all other forms of cancer.

Our cohort was screened for the diagnosis of arthritis (figure 1). Data regarding arthritis were obtained from clinical documentation of observed arthritis during patients’ physical examination by a rheumatologist. Diagnosed arthritis was characterised according to the affected joints. The diagnosis of spondyloarthritis (SpA), RA, psoriatic arthritis (PsA) or JIA was accepted when diagnosis was made by a rheumatologist and when the respective classification criteria were fulfilled: the Assessment of SpondyloArthritis International Society classification criteria for SpA,¹⁷ the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA,¹⁸ the Classification Criteria for Psoriatic Arthritis for PsA¹⁹ and the International League of Associations for Rheumatology classification of JIA.²⁰

Figure 1. Study design. ASAS, Assessment of Spondyloarthritis International Society; CASPAR, Classification Criteria for Psoriatic Arthritis; CVID, common variable immunodeficiency; JIA, juvenile idiopathic arthritis; PAD, primary antibody deficiency; RA, rheumatoid arthritis; SpA, spondyloarthropathy; SPAD, specific polysaccharide antibody deficiency.

Available serological findings, including rheumatoid factor (RF) test, cyclic citrullinated peptide (CCP) antibodies and antinuclear antibodies (ANAs), as well as HLA-B27 antigen test and C reactive protein levels at diagnosis of arthritis, were documented. For patients with arthritis with unknown HLA-B27 status and available DNA probe, we tested for HLA-B27 by PCR. Radiological findings included X-rays and MRI scans of affected joints. Based on the age of onset of arthritis, involved joints, imaging and serological findings, as well as the diagnosis of psoriasis, IBD or an alternative enteropathy, we evaluated classification of arthritis into a known articular rheumatic disorder. Oligoarthritis was defined as arthritis of ≤4 joints, whereas polyarthritis was defined as arthritis affecting ≥5 joints.

Statistical analysis

For statistical calculations, we used GraphPad Prism V.9 (GraphPad, La Jolla, USA). Descriptive statistics are reported as median and IQR in case of continuous variables and as counts and percentages for dichotomous variables. Categorical variables were compared by the Fisher’s exact test. Differences between patients with and without arthritis were evaluated with the Mann-Whitney test. To correct for multiple testing, p values were adjusted for Benjamini-Hochberg false discovery rate (FDR). P values were considered significant if they were lower than a threshold selected to control an FDR of 5%. To evaluate the independent role of variables whose association with arthritis was considered significant in the univariable analysis, we performed multivariable logistic regression analysis.

Results

Characteristics of patients with PAD, prevalence of arthritis and arthritis-associated phenotypes

Patients’ demographic data and characteristics are summarised in table 1. Most patients had a late-onset PAD diagnosed as CVID (216/268, 80.6%). Except for recurrent infections, the majority (202/268, 75.4%) had at least one additional PAD-associated manifestation, which more commonly was an autoimmune disorder (118/268, 44%). Among autoimmune disorders, autoimmune cytopenias were the most prevalent, diagnosed in 45/268 patients (16.8%). Those included ITP in 37/268 patients (13.8%), AIHA in 15/268 patients (5.6%) and autoimmune neutropenia in 2/268 patients (0.7%). With respect to arthritis, except for the case of a patient with XLA who suffered from a septic pneumococcal arthritis at first diagnosis of agammaglobulinaemia and a patient with a late-onset combined immunodeficiency with septic spondylodiscitis, all other cases were diagnosed with inflammatory arthritis. The prevalence of inflammatory arthritis was similar to the one of autoimmune cytopenias (44/268, ie, 16.4%). Female and male patients were equally likely to develop inflammatory arthritis (27/128 vs 17/93, p=0.7391; OR 1.15, 95% CI 0.59 to 2.24). Overall, in 14/44 cases (31.8%) with manifestation of arthritis preceded the diagnosis of PAD. Among PAD-associated manifestations, the diagnosis of arthritis was significantly more common among patients with splenomegaly, enteropathy or an atopic disease (table 2 and online supplemental table 1). All three, splenomegaly, enteropathy and the presence of an atopic disease, were independently associated with the diagnosis of arthritis (online supplemental table 2). We identified no association with psoriasis or infectious manifestations, including gastrointestinal infections. Among diagnosed enteropathies, Crohn’s disease was significantly more common among patients with arthritis (7/44 vs 1/224, p<0.0001; OR 42.2, 95% CI 7 to 477).

Table 1

Characteristics of studied patients with PADs

Characteristic	All N=268	Arthritis n=44	No arthritis n=224	P value
Age (years) (IQR)	47.95 (33.13–61.7)	50.55 (33.25–61.8)	47.7 (33.13–61.3)	0.8448
Sex (male), n (%)	110 (41)	17 (38.63)	93 (41.51)	0.7412
N. European ethnicity, n (%)	252 (94.03)	40 (90.9)	212 (94.64)	0.3093
Age at diagnosis of PID (years) (IQR)	34 (24–46)	34 (23.25–49.5)	33.5 (21.25–46)	0.7598
Age group at diagnosis of PID (years), n (%)
0–4	9 (3.4)	2 (4.54)	7 (3.13)	0.6448
5–17	31 (11.6)	4 (9.09)	27 (12.05)	0.7968
18–29	72 (26.9)	11 (25)	61 (27.23)	0.8536
30–50	101 (37.7)	17 (38.63)	84 (37.5)	1.000
> 50	55 (20.5)	10 (22.72)	45 (20.09)	0.6858
Diagnosis of PID, n (%)
CVID	216 (80.6)	37 (84.09)	179 (79.91)	0.6772
CID	6 (2.2)	1 (2.27)	5 (2.23)	1.000
Unclassified antibody deficiency	13 (4.9)	3 (6.81)	10 (4.46)	0.4537
Agammaglobulinaemia	4 (1.5)	0 (0)	4 (1.79)	1.000
Isolated IgG-subclass deficiency	10 (3.7)	2 (4.54)	8 (3.57)	0.6708
SPAD	1 (0.4)	1 (2.27)	0 (0)	0.1642

CID, combined immunodeficiency; CVID, common variable immunodeficiency; PAD, primary antibody deficiency; PID, primary immunodeficiency; SPAD, specific polysaccharide antibody deficiency.

Table 2

Association of infectious and non-infectious manifestations of PADs with inflammatory arthritis.

Phenotypes	Arthritis N=44	No arthritis N=224	OR (95% CI)	P value	q
Recurrent upper RTIs, n (%)	42 (95.45)	180 (80.36)	5.13 (1.39 to 22.22)	0.0148*	0.0622
Recurrent lower RTIs, n (%)	34 (72.27)	145 (64.73)	1.85 (0.90 to 3.76)	0.1178 (ns)	0.3298
Bronchiectasis, n (%)	12 (27.27)	44 (19.64)	1.53 (0.74 to 3.16)	0.3096 (ns)	0.5201
GLILD, n (%)	4 (9.09)	19 (8.48)	1.08 (0.38 to 3.07)	1.0000 (ns)	0.8842
Granulomatous disease, n (%)	6 (13.64)	22 (9.82)	1.45 (0.57 to 3.66)	0.4256 (ns)	0.5958
Lymphadenopathy, n (%)	20 (45.45)	96 (42.86)	1.11 (0.59 to 2.15)	0.8680 (ns)	0.8578
Splenomegaly, n (%)	12 (27.27)	13 (5.80)	6.09 (2.66 to 13.95)	0.0001****	0.0008
Autoimmune phenomena, n (%)	19 (43.18)	99 (44.20)	0.96 (0.51 to 1.85)	1.0000 (ns)	0.8842
Autoimmune cytopenia, n (%)	9 (20.45)	36 (15.18)	1.34 (0.59 to 3.03)	0.3745 (ns)	0.5720
ITP, n (%)	9 (20.45)	28 (12.5)	1.80 (0.75 to 4.04)	0.1594 (ns)	0.3826
AIHA, n (%)	1 (2.27)	14 (6.25)	0.35 (0.003 to 2.25)	0.4780 (ns)	0.6177
Psoriasis, n (%)	4 (9.09)	9 (20.45)	2.39 (0.78 to 8.13)	0.2383 (ns)	0.4448
Vitiligo, n (%)	3 (6.82)	7 (3.13)	2.27 (0.62 to 8.67)	0.2151 (ns)	0.4448
Atopic disease, n (%)	16 (36.36)	33 (14.73)	3.31 (1.62 to 6.77)	0.0021**	0.0118
Thyreoidopathy, n (%)	6 (13.64)	13 (5.80)	2.56 (0.92 to 6.96)	0.0992 (ns)	0.3298
Enteropathies, n (%)	33 (75)	41 (18.30)	13.39 (6.32 to 28.87)	0.0001****	0.0008
Atrophic gastritis, n (%)	2 (4.55)	6 (2.68)	1.73 (0.34 to 7.16)	0.6217 (ns)	0.6963
Recurrent GI infections, n (%)	7 (15.91)	43 (19.20)	0.80 (0.31 to 1.82)	0.6784 (ns)	0.7123
Malignancy, n (%)	6 (13.64)	24 (10.71)	1.32 (0.52 to 3.26)	0.6012 (ns)	0.6963

*P<0.05, **P<0.01, ****P<0.0001.

P values were adjusted for Benjamini-Hochberg FDR, selected threshold of 5% meaning p values <0.0089 were considered ‘discoveries’ (marked with bold characters).

AIHA, autoimmune haemolytic anaemia; GI, gastrointestinal; GLILD, granulomatous and lymphocytic interstitial lung disease; ITP, immune thrombocytopenic purpura; ns, non-significant; PAD, primary antibody deficiency; RTI, respiratory tract infection.

Clinical subgroups of inflammatory arthritis in pads and CVID

A total of 21/44 (47.7%) cases had oligoarthritis and 23/44 (52.3%) were diagnosed with polyarthritis. The pattern of articular involvement, as well as all relevant extra-articular manifestations for all 44 patients with arthritis, is presented in table 3. Based on the pattern of affected joints, on HLA-B27 positivity and extra-articular disease, such as psoriasis and IBD, arthritis could be classified as a SpA in 31/44 patients (75%) (figure 2A). Those included eight patients with axial spondyloarthritis (axSpA) who displayed sacroiliitis, confirmed through radiographic and/or MRI. In particular, 3/8 patients displayed radiological findings consistent with the diagnosis of radiographic axSpA or ankylosing spondylitis (AS), whereas the rest (ie, 5/8) were diagnosed with a non-radiographic axSpA. A total of 4/44 patients (9.1%), all with a concomitant plaque psoriasis, and 1, who in addition to plaque psoriasis displayed nail psoriasis, fulfilled the classification criteria for PsA. Further, 4/44 patients (9.1%) with early-onset of arthritis, prior to the age of 16 years, could be diagnosed with JIA. Reactive arthritis was diagnosed in 3/44 patients (6.8%) and followed in all three of them an acute gastrointestinal infection.

Figure 2. (A) Summary of ASAS classification criteria, evaluated in 44 patients with arthritis and PAD. Green boxes indicate a fulfilled ASAS criterion, whereas blue and yellow boxes indicate fulfilled criteria for the diagnosis of an axSpA and a perSpA, respectively. Each map column matches a studied patient with arthritis (1-44; see table 3 ). (B) Arthritis workup, available imaging and laboratory investigations. ASAS, Assessment of Spondyloarthritis International Society; axSpA, axial spondyloarthritis; CRP, C reactive protein; PAD, primary antibody deficiency; perSpA, peripheral spondyloarthritis.

Table 3

Clinical description of arthritis

Paient ID	Sex	Age (years)	Age (years) at diagnosis of PID	Age at diagnosis of arthritis	PAD disorder	Arthritis pattern	Extra-articular disease/enteropathy	Arthritis course	Arthritis classification	Actual arthritis treatment
1	M	60	30	36	CVID	Polyarthritis (MCP joints, wrists, knees and ankles)		Chronic and non-erosive	perSpA	NSAID
2	M	49	20	20	CVID	Oligoarthritis (wrists and knee)		Chronic, in remission, since the age of 30 years and manifesting after a giardiasis	ReA	NSAID
3	F	57	35	45	CVID	Polyarthritis (MCP and PIP joints, wrists, elbows and knees)	Enthesitis and Crohn’s disease	Chronic and non-erosive	perSpA	Prednisolone
4	F	62	46	47	CVID	Polyarthritis (DIP and MCP joints, elbows and shoulders), sacroiliitis and syndesmophytes of the lumbar spine	Anterior uveitis	Chronic and non-erosive	r-axSpA	NSAID
5	F	70	46	58	CVID	Polyarthritis (DIP and MCP joints, knee and ankle)	Dactylitis and plaque psoriasis	Chronic and non-erosive	PsA	MTX
6	F	51	4	6	CVID	Polyarthritis (wrists, hips, knees and ankles)		Chronic, erosive and in remission since the age of 19 years	Polyarticular JIA	None
7	F	56	41	52	CVID	Oligoarthritis (MCP and DIP joints and ancle) and multiple tendinitis	NLH, coeliac diseasC	Chronic and non-erosive	Undifferentiated arthritis	LFN
8	M	71	62	57	CVID	Oligoarthritis (ancles)	Recurrent aphthous stomatitis	Chronic and non-erosive	perSpA	NSAID
9	F	31	21	23	CVID	Oligoarthritis (MCP joints)	NLH	Chronic and non-erosive	Undifferentiated arthritis	NSAID
10	F	52	37	27	CVID	Polyarthritis (MCP and PIP joints, knee, ankles and MTP joints		Chronic and non-erosive	perSpA	NSAID
11	M	55	29	38	CVID	Oligoarthritis (wrists and elbow)	Undifferentiated colitis	Chronic and non-erosive	Undifferentiated arthritis	HCQ
12	M	31	22	25	CVID	Oligoarthritis (knees)	Plaque psoriasis, nail psoriasis and multiple bursitis	Chronic and erosive	PsA	MTX
13	F	38	35	34	CVID	Oligoarthritis (wrist and knees) and sacroiliitis		Chronic and non-erosive	nr-axSpA	NSAID
14	F	33	17	17	CVID	Symmetrical polyarthritis (MCP and PIP joints and shoulders)	Undifferentiated colitis	Chronic and non-erosive	perSpA	none
15	F	56	54	40	IgG subclass deficiency	Symmetrical polyarthritis (PIP and MCP joints, shoulders and knees)	Undifferentiated colitis and Raynaud’s phenomenon	Chronic and non-erosive	perSpA	RTX
16	M	71	50	69	Unclassified antibody deficiency	Symmetrical polyarthritis (PIP and MCP joints, wrists and elbows)		Chronic and erosive	Seronegative RA	Baricitinib
17	M	50	50	50	CVID	Oligoarthritis (shoulder and knee)	Raynaud’s phenomenon	Chronic, non-erosive and in remission since the age of 52	perSpA	None
18	F	34	33	34	CVID	Polyarthritis (PIP and MCP joints, hip knees and ankles)		Chronic and non-erosive	perSpA	None
19	M	62	55	56	CVID	Oligoarthritis (PIP joints)	Enthesitis and undifferentiated colitis	Chronic and non-erosive	perSpA	HCQ
20	F	55	22	22	CVID	Symmetrical polyarthritis (MCP and PIP joints, elbows and ankles)		Chronica and non-erosive	Seronegative RA	MTX
21	F	36	20	26	Unclassified antibody deficiency	Oligoarthritis (wrists and ancles)	Sicca symptoms and Crohn’s disease	Chronic and non-erosive	perSpA	RTX
22	F	49	38	41	CVID	Polyarthritis (wrists, knees and ankles)	NLH and undifferentiated colitis	Chronic and non-erosive	perSpA	Abatacept
23	F	63	30	54	CVID	Oligoarthritis (MCP joints) and sacroiliitis		Chronic and non-erosive	nr-axSpA	Prednisolone
24	F	73	47	34	CVID	Polyarthritis (wrists, elbows and knees)	Bursitis suprapatellaris and Coeliac disease	Chronic and non-erosive	perSpA	SSZ
25	F	85	59	66	CVID	Polyarthritis (DIP and PIP joints, wrists and shoulder)	Livedo reticularis, NLC	Chronic and non-erosive	Undifferentiated arthritis	RTX
26	F	33	25	7	CVID	Polyarthritis (wrists, hips, knees, ancles)	Undifferentiated colitis	Chronic and in remission since the age of 12 years	Polyarticular JIA	None
27	F	65	34	34	CVID	Oligoarthritis (wrists, knee) and sacroiliitis		Chronic and non-erosive	nr-axSpA	HCQ+NSAR
28	M	40	13	6	CID	Symmetrical polyarthritis (PIP and MCP joints and knees)	Recurrent enthesitis	Chronic and non-erosive	Polyarticular JIA	RTX
29	F	69	66	53	CVID	Symmetrical polyarthritis (PIP, MCP and MTP joints and elbow)		Chronic and erosive	Seronegative RA	Abatacept
30	M	24	6	21	CVID	Oligoarthritis (MCP joint, knee and ancles)	Recurrent enthesitis and Crohn’s disease	Chronic and erosive	perSpA	Infliximab
31	F	28	18	16	CVID	Polyarthritis (MCP joints, wrists and knees), sacroiliitis and spondylitis	Dactylitis, NLH	Chronic and erosive	r-axSpA	Secukinumab
32	F	57	44	47	SPAD	Sacroiliitis		Chronic and erosive	nr-axSpA	NSAID
33	F	36	30	30	CVID	Oligoarthritis (elbow and knee)	Recurrent bursitis and enthesitis and Crohn’s disease	Chronic and non-erosive	perSpA	HCQ
34	M	38	10	11	CVID	Polyarthritis (MCP joints, wrists and knees)	NLH	Chronic, non-erosive and in remission since the age of 15	Polyarticular JIA	None
35	F	45	34	17	CVID	Polyarthritis (MCP, wrists, shoulder and knees) and sacroiliitis	Crohn’s disease	Chronic and non-erosive	nr-axSpa	Infliximab
36	M	29	4	17	Unclassified antibody deficiency	Oligoarthritis (knees)		Self-limiting and non-erosive	Undifferentiated arthritis	None
37	F	32	23	29	CVID	Oligoarthritis (knees)		Chronic and non-erosive	ReA	Prednisolone
38	M	68	32	33	CVID	Oligoarthritis (wrist and knees)	Plaque psoriasis	Chronic and non-erosive	PsA	None
39	M	32	30	29	CVID	Polyarthritis (MCP and PIP joints, wrists and ankles) and developing after traveller’s diarrhoea		Chronic and non-erosive	ReA	None
40	F	26	21	24	CVID	Oligoarthritis (DIP and PIP joints)	sicca symptoms, dactylitis	chronic, non-erosive	perSpA	SSZ
41	F	55	20	40	CVID	Oligoarthritis (wrists), sacroiliitis, spondylitis and syndesmophytes of the lumbar spine	Raynaud’s phenomenon	Chronic anderosive	r-axSpA	Golimumab
42	F	65	64	33	IgG subclass deficiency	Oligoarthritis (PIP and elbows)	Recurrent enthesitis	Cronic and non-erosive	perSpA	None
43	F	47	26	15	CVID	Polyarthritis (wrists, knees and ancles)	Plaque, psoriasis and NLH	Chronic and non-erosive	PsA	Prednisolone
44	F	24	23	9	CVID	Oligoarthritis (knees and temporomandibular joint)	Crohn’s disease	Chronic and non-erosive	Oligoarticular JIA	MTX+adalimumab

CID, combined immunodeficiency; CVID, common variable immunodeficiency; DIP, distal interphalangeal; F, female; HCQ, hydroxychloroquine; JIA, juvenile idiopathic arthritis; LFN, leflunomide; M, male; MCP, metacarpophalangeal; MTP, metatarsophalangeal; MTX, methotrexate; NLH, nodular lymphoid hyperplasia; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PAD, primary antibody deficiency; perSpA, peripheral spondyloarthritis; PID, primary immunodeficiency disorder; PIP, proximal interphalangeal; PsA, psoriatic arthritis; RA, rheumatoid arthritis; r-axSpA, radiographic axial spondyloarthritis; ReA, reactive arthritis; RTX, rituximab; SPAD, specific polysaccharide antibody deficiency; SSZ, sulfasalazine.

As discussed previously, 33/44 patients with arthritis (75%) had an enteropathy. The subgroup of patients with enteropathy included 12/33 with IBD (6/11 with Crohn’s disease and 6/11 with undifferentiated colitis). A total of 7/33 patients had a biopsy-proven nodular lymphoid hyperplasia (NLH). In addition, two patients were diagnosed with seronegative coeliac disease and the remaining 14 patients had chronic non-infectious diarrhoea, without clear endoscopic or histological evidence for the diagnosis of IBD, NHL or coeliac disease. Arthritis in patients with IBD or an alternative enteropathy may be falling under an enteropathic arthritis.²¹

In addition to typical extra-articular manifestations of SpA, such as psoriasis, dactylitis and IBD, 3/44 patients reported Raynaud’s phenomenon (patients 15, 17 and 41), which may suggest arthritis in the context of a connective tissue disease such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc) or Sjögren’s syndrome (SjS).²² Those three patients, displayed in addition a positive ANA test that would be consistent with the diagnosis of one of the aforementioned connective tissue diseases. However, the rest of relevant classification criteria were not fulfilled.^23–25 Further, 2/44 reported sicca symptoms and displayed a pathological Schirmer’s test (patients 21 and 40) that may suggest the diagnosis of SjS.²⁵ Both of them displayed no ANA or other relevant autoantibodies, and labial salivary biopsy, performed in one of them, was not showing lymphocytic foci and was therefore not in line with the diagnosis of SjS. The presence of SpA-associated manifestations, such as sacroiliitis, dactylitis and IBD (table 3), was rather suggestive of articular inflammation in the context of a SpA in four of previously discussed patients with either Raynaud’s phenomenon or sicca symptoms.

Laboratory findings in patients with PAD with arthritis

Serological investigations are not considered helpful in differentiating arthritis in patients with PAD. Only 2 out of 42 tested patients were RF positive (figure 2A). In one of them (patient 13), sacroiliitis deviated from the joint involvement pattern of a RA, whereas the other (patient 28) had an early-onset arthritis, which was classified as JIA. CCP antibodies were negative in all 26 tested patients. A total of 8 out of 42 studied patients displayed an ANA titre higher than 1:160, and 3 of them displayed a titre higher than 1:320, though in the case of 3/8 patients ANA test has been performed after introduction of immunoglobulin replacement treatment, which may have affected ANA positivity and titre. None of the patients had antibodies against extractable nuclear antigen. Overall, among patients with positive ANA test, the presence of axial joint inflammation or IBD deviated from a typical connective tissue disease-associated arthritis. Ten out of 40 tested patients were HLA-B27 positive (figure 2B). Two out of the 10 patients that were HLA-B27 positive (figure 2A) had an axSpA, including sacroiliitis, whereas the rest were diagnosed with a peripheral SpA. Relatively higher immunoglobulin levels, especially IgA levels, have been long ago reported in patients with AS.^{26 27} Evaluation of the serum immunoglobulin levels at diagnosis of PAD revealed significantly higher IgG values in the subgroup of patients with inflammatory arthritis (p=0.004), whereas IgA and IgM levels were similar between patients with arthritis and those without (figure 3).

Figure 3. Immunoglobulin levels at diagnosis of primary antibody deficiency, prior to the introduction of immunoglobulin replacement treatment (**, p<0.01).

Treatment of arthritis in patients with PADs

A total of 39/44 patients (88.6%) with arthritis were receiving an immunoglobulin replacement therapy. A total of 34/44 patients (77.3%) were on treatment with non-steroidal anti-inflammatory drugs (NSAIDs), prednisolone or various disease-modifying antirheumatic drugs (DMARDs), at last follow-up during the study. In two patients (ie, patients 21 and 23), current immunomodulatory treatment has been primarily commenced to treat ILD. In the remaining 32/44 of patients, arthritis was the reason for treatment with either NSAIDs, prednisolone or a DMARD. Eight out of 44 patients (18.2%) were receiving an NSAID monotherapy. Ten out of 44 patients (22.7%) were treated with a conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), most commonly hydroxychloroquine and methotrexate (MTX). A total of 11/44 patients were on a biological disease-modifying antirheumatic drug (bDMARD) treatment, including 4/44 on a TNF-inhibitor and 3 patients (including patient 21 with a concominant ILD) on rituximab. Anti-inflammatory treatments of patients with arthritis are summarised in table 3. Infectious complications after immunomodulatory treatment for arthritis included oral candidiasis in one patient, during treatment with high-dose steroids and MTX (patient 4) and recurrent oral candidiasis in a patient receiving secukinumab (patient 31), which led to prophylactic treatment with fluconazole. This patient also displayed a higher frequency of sinusitis and bronchitis, which led to antibiotic prophylactic treatment with azithromycin. Further, an additional patient (patient 28) reported a higher frequency of infections during treatment with prednisolone and MTX. The aforementioned anti-inflammatory regimen was ineffective in treating this patient’s polyarthritis and was therefore switched to rituximab, which enabled prednisolone tapering.

Discussion

Rheumatic manifestations and especially arthritis have been variably reported as autoimmune manifestations of PADs.^{12 14 28} In the present retrospective study, in a cohort of patients with PAD, the prevalence of inflammatory arthritis amounted to approximately 16%, which is higher than previously reported.^9–12 The latter might be explained through selection bias, due to the fact that our outpatient clinic is a tertiary referral centre both for rheumatic disorders and primary immunodeficiency disorders (PIDs). We further aimed at providing a comprehensive characterisation of the course, the pattern of articular involvement and the associated extra-articular manifestations of inflammatory arthritis. Among established rheumatological entities characterised by articular inflammation, we find that PAD-associated arthritis can be commonly classified as SpA. Clinical features such as anterior uveitis, psoriasis, enthesitis, dactylitis and/or the coexistence of IBD mainly accounted for that. Further, association of arthritis with an enteropathy may represent a feature overlapping with enteropathic arthritis, especially in the subgroup of patients with IBD. In addition to enteropathy, arthritis associated with the presence of splenomegaly, which comes in line with previous reports associating autoimmunity with splenomegaly in CVID.^{29 30}

Inflammatory arthritis represents the most common extra-articular manifestation of IBD.³¹ Further, the observation that arthritis can be the consequence of gastrointestinal infection in genetically predisposed subjects has provided an additional link between gastrointestinal and articular inflammation.³² Besides IBD-associated arthritis and postenteritis reactive arthritis, other gastrointestinal conditions, such as coeliac disease, Whipple disease and intestinal bypass, are associated with arthritis, highlighting a link between the gut and articular inflammation.^{32 33} Although the precise aetiology of arthritis in each of the aforementioned conditions remains unknown, they cumulatively suggest a gut component in its pathogenesis, entailing the interplay of microbial factors with host factors, which may result in bacterial overgrow, dysbiosis as well as in gastrointestinal inflammation and gut barrier dysfunction.

Gut microbiota and the integrity of the gut barrier have been suggested to contribute the development of arthritis, also in the absence of a manifest gastrointestinal condition.^34–37 In RA, enhanced gut permeability has been reported to correlate with disease onset and activity as well as with tumour necrosis factor (TNF) inhibitor-induced remission, providing a likely mechanistic link between gut microbiota and articular inflammation. Changes in the composition of the gut microbiome have been reported in faecal and biopsy samples from patients with SpA, and the abundance of particular bacteria has been associated with disease activity.³⁸ Further, in ileal biopsies from patients with SpA, the presence of adherent and invading bacteria associated with decreased expression of tight junction components.³⁹ The latter, together with similar findings in HLA-B27 rats, suggests the relevance of dysbiosis and impaired gut barrier function in the pathogenesis of inflammation in SpA.^38–40

Gastrointestinal inflammation is common in patients with PADs, and nearly half of patients with CVID with gastrointestinal symptoms who have undergone colonoscopy have been reported to display a non-infectious pathology, including NLH, microscopic colitis and IBD.^{41 42} Bacterial dysbiosis has been also identified in CVID, though evidence on its role in the pathogenesis of autoimmunity remains scarce.⁴³ PAD-associated dysbiosis may stem from decreased secretory IgA, infections, antibiotics as well as dietary factors.^43–45 In addition, microbial-related as well as the PAD-intrinsic antibody failure and associated enteropathies may compromise anatomical containment of commensal organisms in the gut.⁴³ The latter may result in release of microbiota-derived products into the systemic circulation and consequently in systemic innate immune activation and higher risk for inflammatory complications, including arthritis.⁴⁴ Given the aforementioned discussed association of both SpA and CVID with gut inflammation and gut dysbiosis, our observation that hypogammaglobulinaemic arthritis associates with enteropathy may extend the relevance of the gut–joint axis hypothesis to PAD-associated inflammatory arthritis.

The strong association of immunodeficiency with autoimmunity suggests that pathogenic pathways of immunological disorders can overlap.⁴⁶ Those include defects in molecules with pleiotropic roles within the immune system or B cell-intrinsic and especially T cell-intrinsic defects may account for both immunodeficiency and autoimmunity. Impaired response to infections could also account for autoimmunity through diverse pathomechanisms, including molecular mimicry, superantigen-induced immune activation, release and enhanced presentation of self-antigens. ^{46 47} The role of altered microbiota and impaired gut barrier may represent an additional mechanism of autoimmunity in PADs, which needs to be further investigated.

We finally found an association between atopic diseases and inflammatory arthritis in PADs. Focusing on each of the relatively common atopic diseases in our cohort, all three allergic rhinitis, atopic dermatitis and allergic asthma tended to be associated with arthritis. However, the role of each allergic condition needs to be evaluated in larger cohorts of patients with PAD. Several previous studies have evaluated the association between atopy and rheumatic disorders. Retrospective studies have demonstrated the association of asthma, atopic dermatitis and allergic rhinitis with RA.^48–50 Further, AS has been reported to be associated with increased risk for atopic disease in the form of asthma and allergic rhinitis.⁵¹ Shared risk factors including genetic and environmental factors, such as smoking as well as overlapping pathomechanisms of immune dysregulation, including enhanced Th2 or Th17 diffetentiation and epithelial barrier dysfunction, may be relevant for the association of allergy with inflammatory arthritis.⁵⁰

Treatment of arthritis was the same as in other rheumatological disorders and depended on the presence of axial joint inflammation as well as on comorbidities, such as ILD or IBD. In approximately 22% of studied patients, arthritis displayed a sustained remission in the absence of an anti-inflammatory treatment, which would be consistent with a self-limiting or monophasic disease course. Further, only in the case of a single patient anti-inflammatory arthritis was modified due to the activity of arthritis, which suggests a satisfactory therapeutic efficacy of chosen treatments. However, the possibility of avoiding DMARD treatment in patients with residual arthritis activity for fear of severe infections cannot be excluded,⁵² as standard measures for the evaluation of arthritis activity, such as the patient global assessment of disease activity or functional questionnaires, were not available. Further, prospective documentation of infectious manifestations under treatment with diverse csDMARDs and bDMARDs would clarify the influence of immunomodulatory treatment on infectious susceptibility in patients with PIDs.

Standard laboratory work-up of inflammatory arthritis included the measurement of autoantibodies, such ANA and RF as well as HLA-B27 test. Among patients with arthritis, the positivity rate of HLA-B27 amounted 25% and was therefore higher than the previously reported positivity of 10% in the German population.⁵³ However, among the seven tested patients with axSpA, only two patients harboured HLA-B27, which suggests that susceptibility to arthritis including axial joint inflammation cannot be explained through HLA-B27 in the majority of patients with arthritis. Serological tests are of limited diagnostic value in patients with PAD, which—considering the present study—can be expanded to the differentiation of arthritis. However, the loss of antibody responses, which usually is an intrinsic feature of PADs, may have biased arthritis classification towards seronegative SpA. ANA positivity was in most cases due to a low antibody titre and could in case of some patients suggest the diagnosis of connective tissue disease, such as SLE or SSc, though relevant criteria were not fulfilled.

Our study has several limitations. As discussed previously, high frequency of inflammatory arthritis may reflect a selection bias due to fact that the present study has been conducted in a tertiary centre, which may result in under-representation of the ‘infections-only’ subgroup of patients. In addition, factors intrinsic to the retrospective study design affected evaluation of the therapeutic efficacy and tolerability of drugs employed to treat arthritis. Evaluation of tolerability would be especially relevant in view of the immunosuppressive effect of diverse csDMARDs and dDMARDs, which may worsen the PAD-intrinsic immunodeficiency.⁵⁴⁴¹ In the present study, only a minority of patients developed infectious complication as a consequence of their arthritis treatment, which may underestimate the impact of DMARDs and their immunosuppressive effect on patients’ immunodeficiency. The latter may depend on several parameters, including concomitant glucocorticoid treatment, the type of PAD as well as the vaccination status of tested patients, which should be evaluated through perspective studies with large numbers of treated patients.

In summary, our findings suggest that inflammatory arthritis is a common phenotypical trait of PADs. The PAD-intrinsic tendency to seronegative disease, together with the extra-articular manifestations associated with arthritis in PAD, represents features that overlap with SpA. Especially the association of arthritis in PADs with enteropathies suggests the likely pathogenic relevance of the gut–joint axis hypothesis, which needs to be further investigated.

We thank all nurses, physicians and documentation personnel of the outpatient clinics of the Department of Rheumatology and Immunology of the Hannover Medical School for collecting blood samples, informing the patients about the study and documenting patients’ medications.

Data availability statement

Data are available for formal research purposes only upon request to the corresponding author.

Ethics statements

Patient consent for publication

All studied patients signed an informed consent form.

Ethics approval

This study was conducted in accordance with the Declaration of Helsinki and was also approved by the ethical committee of the Hannover Medical School (approval number 5582; 8875_BO_K_2020). All patients signed an informed consent form.

Footnote

Contributors GS conceived and planned the study. GS and NMP took the lead in writing the manuscript. FA, DE and TW significantly contributed to drafting and revision of the paper. NMP and CCP contributed substantially to data acquisition and interpretation. GS is responsible for the overall content of this work as a guarantor. GS and NMP performed the statistical analysis. All authors approved the final version.

Funding This project was funded by the Rosemarie-Germscheid foundation. It was additionally supported by the Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany’s Excellence Strategy (EXC 2155 'RESIST', project ID 39087428) and the German network for multiorgan autoimmune diseases (GAIN_01GM1910E) and the German Center for Infection Research (DZIF TTU 01.801).

Competing interests None declared.

Patient and public involvement statement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

References

¹ Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. Nat Rev Immunol 2013; 13: 519–33. doi:10.1038/nri3466 http://www.ncbi.nlm.nih.gov/pubmed/23765059

² Shin JJ, Liauw D, Siddiqui S, et al. Immunological and clinical phenotyping in primary antibody deficiencies: a growing disease spectrum. J Clin Immunol 2020; 40: 592–601. doi:10.1007/s10875-020-00773-y http://www.ncbi.nlm.nih.gov/pubmed/32239366

³ Bonilla FA, Barlan I, Chapel H, et al. International consensus document (icon): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract 2016; 4: 38–59. doi:10.1016/j.jaip.2015.07.025 http://www.ncbi.nlm.nih.gov/pubmed/26563668

⁴ Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009; 145: 709–27. doi:10.1111/j.1365-2141.2009.07669.x http://www.ncbi.nlm.nih.gov/pubmed/19344423

⁵ Mucke J, Cornet A, Witte T, et al. Association of common variable immunodeficiency and rare and complex connective tissue and musculoskeletal diseases. A systematic literature review. Clin Exp Rheumatol 2022; 40 Suppl 134: 40–5. doi:10.55563/clinexprheumatol/bbuvih http://www.ncbi.nlm.nih.gov/pubmed/35349404

⁶ Rawat A, Jindal AK, Suri D, et al. Clinical and genetic profile of X-linked agammaglobulinemia: a multicenter experience from India. Front Immunol 2020; 11: 612323. doi:10.3389/fimmu.2020.612323 http://www.ncbi.nlm.nih.gov/pubmed/33584693

⁷ Cardenas-Morales M, Hernandez-Trujillo VP. Agammaglobulinemia: from X-linked to autosomal forms of disease. Clin Rev Allergy Immunol 2022; 63: 22–35. doi:10.1007/s12016-021-08870-5 http://www.ncbi.nlm.nih.gov/pubmed/34241796

⁸ Kim J-H, Park H-J, Choi G-S, et al. Immunoglobulin G subclass deficiency is the major phenotype of primary immunodeficiency in a Korean adult cohort. J Korean Med Sci 2010; 25: 824–8. doi:10.3346/jkms.2010.25.6.824 http://www.ncbi.nlm.nih.gov/pubmed/20514300

⁹ Barton JC, Barton JC, Bertoli LF, et al. Characterization of adult patients with IgG subclass deficiency and subnormal IgG2. PLoS One 2020; 15: e0240522. doi:10.1371/journal.pone.0240522 http://www.ncbi.nlm.nih.gov/pubmed/33048985

¹⁰ Mormile I, Punziano A, Riolo CA, et al. Common variable immunodeficiency and autoimmune diseases: a retrospective study of 95 adult patients in a single tertiary care center. Front Immunol 2021; 12. doi:10.3389/fimmu.2021.652487 http://www.ncbi.nlm.nih.gov/pubmed/34290696

¹¹ Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92: 34–48. doi:10.1006/clim.1999.4725 http://www.ncbi.nlm.nih.gov/pubmed/10413651

¹² Azizi G, Kiaee F, Hedayat E, et al. Rheumatologic complications in a cohort of 227 patients with common variable immunodeficiency. Scand J Immunol 2018; 87: e12663. doi:10.1111/sji.12663 http://www.ncbi.nlm.nih.gov/pubmed/29574865

¹³ Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Ann Allergy Asthma Immunol 2019; 123: 454–60. doi:10.1016/j.anai.2019.07.014 http://www.ncbi.nlm.nih.gov/pubmed/31349011

¹⁴ Swierkot J, Lewandowicz-Uszynska A, Chlebicki A, et al. Rheumatoid arthritis in a patient with common variable immunodeficiency: difficulty in diagnosis and therapy. Clin Rheumatol 2006; 25: 92–4. doi:10.1007/s10067-005-1141-6 http://www.ncbi.nlm.nih.gov/pubmed/15940551

¹⁵ Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract 2019; 7: 1763–70. doi:10.1016/j.jaip.2019.02.004 http://www.ncbi.nlm.nih.gov/pubmed/30776527

¹⁶ Bruns L, Panagiota V, von Hardenberg S, et al. Common variable Immunodeficiency-Associated cancers: the role of clinical phenotypes, immunological and genetic factors. Front Immunol 2022; 13: 742530. doi:10.3389/fimmu.2022.742530 http://www.ncbi.nlm.nih.gov/pubmed/35250968

¹⁷ Rudwaleit M, van der Heijde D, Landewé R, et al. The assessment of spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70: 25–31. doi:10.1136/ard.2010.133645 http://www.ncbi.nlm.nih.gov/pubmed/21109520

¹⁸ Aletaha D, Neogi T, Silman AJ. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2010; 2010: 2569–81.

¹⁹ Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665–73. doi:10.1002/art.21972 http://www.ncbi.nlm.nih.gov/pubmed/16871531

²⁰ Petty RE, Southwood TR, Manners P, et al. International League of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390–2. http://www.ncbi.nlm.nih.gov/pubmed/14760812

²¹ İlgen U, Emmungil H. Enteropathic arthritis beyond the criteria. Inflamm Bowel Dis 2022; 28: e51–2. doi:10.1093/ibd/izab269 http://www.ncbi.nlm.nih.gov/pubmed/34757420

²² Curtiss P, Svigos K, Schwager Z, et al. Part I: epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud's phenomenon. J Am Acad Dermatol 2022. doi: doi:10.1016/j.jaad.2022.06.1199. [Epub ahead of print: 06 Jul 2022 ]. http://www.ncbi.nlm.nih.gov/pubmed/35809798

²³ Aringer M, Costenbader K, Daikh D. European League against Rheumatism/American College of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 2019: 1151–9.

²⁴ van den Hoogen F, Khanna D, Fransen J. Classification criteria for systemic sclerosis: an American College of rheumatology/European League against rheumatism collaborative initiative. Ann Rheum Dis 2013; 2013: 1747–55.

²⁵ Shiboski CH, Shiboski SC, Seror R. American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2016; 2017: 9–16.

²⁶ Hocini H, Iscaki S, Benlahrache C, et al. Increased levels of serum IgA as IgA1 monomers in ankylosing spondylitis. Ann Rheum Dis 1992; 51: 790–2. doi:10.1136/ard.51.6.790 http://www.ncbi.nlm.nih.gov/pubmed/1616365

²⁷ Veys EM, van Leare M, IgG S. Serum IgG, IgM, and IgA levels in ankylosing spondylitis. Ann Rheum Dis 1973; 32: 493–6. doi:10.1136/ard.32.6.493 http://www.ncbi.nlm.nih.gov/pubmed/4202498

²⁸ Sogkas G, Dubrowinskaja N, Adriawan IR, et al. High frequency of variants in genes associated with primary immunodeficiencies in patients with rheumatic diseases with secondary hypogammaglobulinaemia. Ann Rheum Dis 2021; 80: 392–9. doi:10.1136/annrheumdis-2020-218280 http://www.ncbi.nlm.nih.gov/pubmed/33046446

²⁹ Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112: 277–86. doi:10.1182/blood-2007-11-124545 http://www.ncbi.nlm.nih.gov/pubmed/18319398

³⁰ Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008; 111: 77–85. doi:10.1182/blood-2007-06-091744 http://www.ncbi.nlm.nih.gov/pubmed/17898316

³¹ Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116–22. doi:10.1111/j.1572-0241.2001.03756.x http://www.ncbi.nlm.nih.gov/pubmed/11316157

³² Gracey E, Vereecke L, McGovern D, et al. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol 2020; 16: 415–33. doi:10.1038/s41584-020-0454-9 http://www.ncbi.nlm.nih.gov/pubmed/32661321

³³ Peluso R, Di Minno MND, Iervolino S, et al. Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol 2013; 2013: 1–12. doi:10.1155/2013/631408 http://www.ncbi.nlm.nih.gov/pubmed/23690825

³⁴ Van Praet L, Van den Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013; 72: 414–7. doi:10.1136/annrheumdis-2012-202135 http://www.ncbi.nlm.nih.gov/pubmed/23139267

³⁵ Van Praet L, Jans L, Carron P, et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the giant cohort. Ann Rheum Dis 2014; 73: 1186–9. doi:10.1136/annrheumdis-2013-203854 http://www.ncbi.nlm.nih.gov/pubmed/24276368

³⁶ Matei DE, Menon M, Alber DG, et al. Intestinal barrier dysfunction plays an integral role in arthritis pathology and can be targeted to ameliorate disease. Med 2021; 2: 864–83. doi:10.1016/j.medj.2021.04.013 http://www.ncbi.nlm.nih.gov/pubmed/34296202

³⁷ Tajik N, Frech M, Schulz O, et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nat Commun 2020; 11: 1995. doi:10.1038/s41467-020-15831-7 http://www.ncbi.nlm.nih.gov/pubmed/32332732

³⁸ So J, Tam L-S. Gut microbiome and its interaction with immune system in spondyloarthritis. Microorganisms 2020; 8: 1727. doi:10.3390/microorganisms8111727 http://www.ncbi.nlm.nih.gov/pubmed/33158167

³⁹ Ciccia F, Guggino G, Rizzo A, et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis 2017; 76: 1123–32. doi:10.1136/annrheumdis-2016-210000 http://www.ncbi.nlm.nih.gov/pubmed/28069576

⁴⁰ Qaiyum Z, Lim M, Inman RD. The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights. Semin Immunopathol 2021; 43: 173–92. doi:10.1007/s00281-021-00845-0 http://www.ncbi.nlm.nih.gov/pubmed/33625549

⁴¹ Pikkarainen S, Martelius T, Ristimäki A, et al. A high prevalence of gastrointestinal manifestations in common variable immunodeficiency. Am J Gastroenterol 2019; 114: 648–55. doi:10.14309/ajg.0000000000000140 http://www.ncbi.nlm.nih.gov/pubmed/30747770

⁴² Agarwal S, Cunningham-Rundles C. Gastrointestinal manifestations and complications of primary immunodeficiency disorders. Immunol Allergy Clin North Am 2019; 39: 81–94. doi:10.1016/j.iac.2018.08.006 http://www.ncbi.nlm.nih.gov/pubmed/30466774

⁴³ Varricchi G, Poto R, Ianiro G, et al. Gut microbiome and common variable immunodeficiency: few Certainties and many outstanding questions. Front Immunol 2021; 12: 712915. doi:10.3389/fimmu.2021.712915 http://www.ncbi.nlm.nih.gov/pubmed/34408753

⁴⁴ Sterlin D, Fadlallah J, Slack E, et al. The antibody/microbiota interface in health and disease. Mucosal Immunol 2020; 13: 3–11. doi:10.1038/s41385-019-0192-y http://www.ncbi.nlm.nih.gov/pubmed/31413347

⁴⁵ Ho H-E, Radigan L, Bongers G, et al. Circulating bioactive bacterial DNA is associated with immune activation and complications in common variable immunodeficiency. JCI Insight 2021; 6: e144777. doi:10.1172/jci.insight.144777 http://www.ncbi.nlm.nih.gov/pubmed/34622805

⁴⁶ Sogkas G, Atschekzei F, Adriawan IR, et al. Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity. Cell Mol Immunol 2021; 18: 1122–40. doi:10.1038/s41423-020-00626-z http://www.ncbi.nlm.nih.gov/pubmed/33795850

⁴⁷ Fujinami RS, von Herrath MG, Christen U, et al. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 2006; 19: 80–94. doi:10.1128/CMR.19.1.80-94.2006 http://www.ncbi.nlm.nih.gov/pubmed/16418524

⁴⁸ Kronzer VL, Westerlind H, Alfredsson L, et al. Allergic conditions and risk of rheumatoid arthritis: a Swedish case-control study. RMD Open 2022; 8: e002018. doi:10.1136/rmdopen-2021-002018 http://www.ncbi.nlm.nih.gov/pubmed/35168998

⁴⁹ Kronzer VL, Crowson CS, Sparks JA, et al. Investigating asthma, allergic disease, passive smoke exposure, and risk of rheumatoid arthritis. Arthritis Rheumatol 2019; 71: 1217–24. doi:10.1002/art.40858 http://www.ncbi.nlm.nih.gov/pubmed/30747496

⁵⁰ Lai N-S, Tsai T-Y, Koo M, et al. Association of rheumatoid arthritis with allergic diseases: a nationwide population-based cohort study. Allergy Asthma Proc 2015; 36: 99–103. doi:10.2500/aap.2015.36.3871 http://www.ncbi.nlm.nih.gov/pubmed/26314811

⁵¹ Chang W-P, Kuo C-N, Kuo L-N, et al. Increase risk of allergic diseases in patients with ankylosing spondylitis: a 10-year follow-up population-based study in Taiwan. Medicine 2016; 95: e5172. doi:10.1097/MD.0000000000005172 http://www.ncbi.nlm.nih.gov/pubmed/27828843

⁵² Kralickova P, Mala E, Vokurkova D, et al. Cytomegalovirus disease in patients with common variable immunodeficiency: three case reports. Int Arch Allergy Immunol 2014; 163: 69–74. doi:10.1159/000355957 http://www.ncbi.nlm.nih.gov/pubmed/24247002

⁵³ Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58–67. doi:10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G http://www.ncbi.nlm.nih.gov/pubmed/9433870

⁵⁴ Jablonka A, Etemadi H, Adriawan IR, et al. Peripheral blood lymphocyte phenotype differentiates secondary antibody deficiency in rheumatic disease from primary antibody deficiency. J Clin Med 2020; 9: 1049. doi:10.3390/jcm9041049 http://www.ncbi.nlm.nih.gov/pubmed/32272789